

Open Peer Review on Qeios

Indium In 111 Daclizumab

National Cancer Institute

Source

National Cancer Institute. <u>Indium In 111 Daclizumab</u>. NCI Thesaurus. Code C29230.

A radioimmunoconjugate comprised of daclizumab, a recombinant humanized monoclonal antibody directed against the alpha subunit of the interleukin-2 (IL-2) receptor (IL-2RA, TAC antigen, CD25), which is labeled with the gamma-emitting isotope indium 111 (In 111; 111In), with potential radioimaging application. Upon administration, indium In 111 daclizumab targets and binds to IL-2RA and inhibits the binding of IL-2, thereby blocking IL-2-mediated activation of lymphocytes. IL-2RA is not expressed by normal resting lymphoid cells, with the exception of regulatory T-cells (Tregs), but it is expressed on a minority of Reed-Sternberg cells and, is overexpressed on T-cells rosetting around Reed-Sternberg cells in certain lymphomas. The use of gamma scintigraphy permits the immunodetection of IL-2RA expressing cells.